Clozapine Augmentation Strategies

Overview

Journal Ment Health Clin

Specialty Psychiatry

Date 2019 Dec 21

PMID 31857930

Citations 9

Authors

James L Roerig

Affiliations

Soon will be listed here.

Abstract

Clozapine is established as the gold standard for antipsychotic treatment of patients suffering from treatment-resistant schizophrenia. Over virtually 3 decades, the level of inadequate response to clozapine was found to range from 40% to 60%. A heightened interest developed in the augmentation of clozapine to try to achieve response or maximize partial response. A large variety of drug groups have been investigated. This article focuses on the meta-analyses of these trials to discover reasonable evidence-based approaches to the management of patients not responding to clozapine.

Citing Articles

Knowledge domain and trends in treatment-resistant schizophrenia (TRS) research based on CiteSpace bibliometrics analysis.

Cai H, Du R, Zhang J, Wang X, Li W, Yang K Front Pharmacol. 2024; 15:1478625.

PMID: 39564115 PMC: 11573587. DOI: 10.3389/fphar.2024.1478625.

Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients.

Li Y, Zhu M, Dong Y, Liu N, Wang X, Yang B Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 39196353 DOI: 10.1007/s00406-024-01885-x.

Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia.

Peitl V, Puljic A, Skrobo M, Nadalin S, Dunkic L, Karlovic D Biomedicines. 2023; 11(4).

PMID: 37189691 PMC: 10135858. DOI: 10.3390/biomedicines11041072.

Efficacy of Electroconvulsive Therapy for the Treatment of Movement Disorders: A Literature Review.

Muhammad N, Brooks Iii N, Chatham L, Chatham A, Muthukanagaraj P Cureus. 2023; 15(3):e36634.

PMID: 36968685 PMC: 10038173. DOI: 10.7759/cureus.36634.

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.

Zhu M, Liu Z, Hu Q, Yang J, Jin Y, Zhu N Mil Med Res. 2022; 9(1):59.

PMID: 36253804 PMC: 9578180. DOI: 10.1186/s40779-022-00420-0.

References

Conley R, Carpenter Jr W, Tamminga C . Time to clozapine response in a standardized trial. Am J Psychiatry. 1997; 154(9):1243-7. DOI: 10.1176/ajp.154.9.1243. View

Leach M, Baxter M, Critchley M . Neurochemical and behavioral aspects of lamotrigine. Epilepsia. 1991; 32 Suppl 2:S4-8. DOI: 10.1111/j.1528-1157.1991.tb05882.x. View

Rajkumar A, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob K . Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2012; 28(1):50-6. DOI: 10.1097/YIC.0b013e32835ac9da. View

Gillespie A, Samanaite R, Mill J, Egerton A, MacCabe J . Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry. 2017; 17(1):12. PMC: 5237235. DOI: 10.1186/s12888-016-1177-y. View

Panchal S, Ondo W . Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. Curr Psychiatry Rep. 2018; 20(1):3. DOI: 10.1007/s11920-018-0869-z. View

Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W . Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017; 16(1):77-89. PMC: 5269492. DOI: 10.1002/wps.20387. View

Siskind D, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B . Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2018; 52(8):751-767. DOI: 10.1177/0004867418772351. View

Barbui C, Signoretti A, Mule S, Boso M, Cipriani A . Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull. 2008; 35(2):458-68. PMC: 2659302. DOI: 10.1093/schbul/sbn030. View

Meltzer H, Burnett S, Bastani B, Ramirez L . Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 1990; 41(8):892-7. DOI: 10.1176/ps.41.8.892. View

10.

Veerman S, Schulte P, Deijen J, de Haan L . Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med. 2016; 47(2):363-375. DOI: 10.1017/S0033291716002476. View

11.

Wang G, Zheng W, Li X, Wang S, Cai D, Yang X . ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. J Psychiatr Res. 2018; 105:23-32. DOI: 10.1016/j.jpsychires.2018.08.002. View

12.

Egerton A, Reid L, McKerchar C, Morris B, Pratt J . Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl). 2005; 179(1):77-84. DOI: 10.1007/s00213-004-2109-y. View

13.

Tiihonen J, Wahlbeck K, Kiviniemi V . The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009; 109(1-3):10-4. DOI: 10.1016/j.schres.2009.01.002. View

14.

Nielsen J, Damkier P, Lublin H, Taylor D . Optimizing clozapine treatment. Acta Psychiatr Scand. 2011; 123(6):411-22. DOI: 10.1111/j.1600-0447.2011.01710.x. View

15.

Zheng W, Xiang Y, Yang X, Xiang Y, De Leon J . Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2017; 78(5):e498-e505. DOI: 10.4088/JCP.16r10782. View

16.

Czobor P, Van Dorn R, Citrome L, Kahn R, Fleischhacker W, Volavka J . Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015; 25(8):1158-66. PMC: 4860611. DOI: 10.1016/j.euroneuro.2015.04.003. View

17.

Essock S, Hargreaves W, Covell N, Goethe J . Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996; 32(4):683-97. View

18.

De Lucena D, Fernandes B, Berk M, Dodd S, Medeiros D, Pedrini M . Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009; 70(10):1416-23. DOI: 10.4088/JCP.08m04935gry. View

19.

Koponen H, Leinonen E, Lepola U . Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol. 1996; 6(1):69-71. DOI: 10.1016/0924-977x(95)00069-2. View

20.

Kayser M, Titulaer M, Gresa-Arribas N, Dalmau J . Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013; 70(9):1133-9. PMC: 3809325. DOI: 10.1001/jamaneurol.2013.3216. View